Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label pediatric tofacitinib study in moderately to severely active ulcerative colitis
NL-OMON52309Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tofacitinib in autoimmune colitis and inflammatory bowel disease (IBD) (4 arms), sponsored by Pfizer. Primary endpoint: Remission by central read Mayo score at maintenance Week 44. Started Jun 2024; status: recruiting.
02
Drugs
03
Conditions
autoimmune colitisinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON52309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52309.